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Abstract
Background: Clinical Trials (CTs) are essential for bridging the gap between experimental research on new drugs and their
clinical application. Just like CTs for traditional drugs and biologics have helped accelerate the translation of biomedical
findings into medical practice, CTs for nanodrugs and nanodevices could advance novel nanomaterials as agents for
diagnosis and therapy. Although there is publicly available information about nanomedicine-related CTs, the online
archiving of this information is carried out without adhering to criteria that discriminate between studies involving
nanomaterials or nanotechnology-based processes (nano), and CTs that do not involve nanotechnology (non-nano). Finding
out whether nanodrugs and nanodevices were involved in a study from CT summaries alone is a challenging task. At the
time of writing, CTs archived in the well-known online registry ClinicalTrials.gov are not easily told apart as to whether they
are nano or non-nano CTs—even when performed by domain experts, due to the lack of both a common definition for
nanotechnology and of standards for reporting nanomedical experiments and results.
Methods: We propose a supervised learning approach for classifying CT summaries from ClinicalTrials.gov according to
whether they fall into the nano or the non-nano categories. Our method involves several stages: i) extraction and manual
annotation of CTs as nano vs. non-nano, ii) pre-processing and automatic classification, and iii) performance evaluation
using several state-of-the-art classifiers under different transformations of the original dataset.
Results and Conclusions: The performance of the best automated classifier closely matches that of experts (AUC over 0.95),
suggesting that it is feasible to automatically detect the presence of nanotechnology products in CT summaries with a high
degree of accuracy. This can significantly speed up the process of finding whether reports on ClinicalTrials.gov might be
relevant to a particular nanoparticle or nanodevice, which is essential to discover any precedents for nanotoxicity events or
advantages for targeted drug therapy.
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Introduction
Because of their nanoscale biophysical and biochemical
interaction characteristics, products containing nanomaterials or
involving the application of nanotechnology behave very differ-
ently than traditional bulk materials used in therapeutics [1]. For
instance, on the positive side, nanotechnology products can have
increased bioavailability and potency, decreased toxicity and the
enabling of highly targeted drug delivery, among many other
advantages [2], making them potentially valuable for medical
applications. However, experimental research in nanomedicine is
still in its infancy, and many nanoparticles and nanotechnologies
have the potential of also producing complex and poorly
understood toxic side-effects [3]. As result, discovering and
reporting of in vivo effects of nanoparticles in experimental
studies and CTs to supplement theoretical predictions and results
of in vitro studies [3,4] is fundamental to advance the discovery
and use of nanomaterials as beneficial agents for medical diagnosis
and therapy. Clinical Trials (CTs) of nanoparticles and nanode-
vices may lead to novel treatments and diagnostic tools, as well as
complement or supplement existing products that are currently
being nanomanufactured to address clinical needs (e.g. effective-
ness) while avoiding the undesirable side-effects (e.g. toxicity) [5,6].
Over the past years, there has been a proliferation of pre-clinical
and clinical studies on nanopharmaceuticals [7]. Unfortunately,
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online archiving of nanomedical clinical data has been usually
done without following any specific criteria, thus not making a
distinction between those studies at the nanoscale focused on
testing nanodrugs and nanodevices (nano CTs) and CTs on
regular drugs and biologics that do not involve nanotechnology
(non-nano CTs). Thus, it is becoming difficult to develop a broad
and comprehensive perspective on the current status and impact of
nanotechnology products in the clinical context.
A number of articles have analyzed published trial results in
terms of quality and completeness [8,9], as well as the impact of
the public release of CTs [10–12], but these and other studies have
not yet made, to our knowledge, such a clear distinction between
nano and non-nano categories either. Recent publications in the
scientific literature have reviewed specific medical applications of
nanotechnology-based pharmaceuticals, but these publications
only reported a few specific nano-level products currently reported
positively in CTs [7,13–14] and certain nanodrug patents [15–17].
We believe that the automatic annotation of CT reports to tell
whether they are nano or not, can be of great help to clinical
researchers in nanomedicine, and we will show in this paper that
such a classification can come from comprehensively searching for,
and detecting the presence of nanodrug and nanodevice involve-
ment in a study from the CT summaries published in public
registries, such as ClinicalTrials.gov.
The analysis of nanoinformation—a new field, to which we
have already contributed [18–21]—suggests that data resulting
from research in nanomedicine are highly heterogeneous, and
distributed among many data sources, without usually following
any specific data standard or using a controlled vocabulary [22].
Since the volume of nanomedicine experimental and clinical data
is increasing rapidly, manual searches, and subsequent analyses
and annotation of studies on nanodrugs and nanodevices, does not
scale, and becomes increasingly infeasible [23]. In this paper, we
present a novel approach for the analysis of summaries of CTs,
designed to detect the mention of nanotechnology products as test
targets, as opposed to the testing of conventional drugs in a trial, so
as to demonstrate the viability of applying automatic methods to
carrying out the detection, and suggesting, by our cross-validation
results, that the techniques can be extended to predictive detection
and annotation of the CTs.
Clinical Trials for Nanomedicine
A major issue when analyzing a nanomedical text is how to
define the term ‘‘nano’’ [24]. Many attempts to characterize
nanotechnology can be found in the literature [25] but a standard
or consensus definition—proposed or accepted by all the
regulatory authorities in the field—has yet to be established. For
instance, the International Organization for Standardization (ISO)
and the US National Nanotechnology Initiative (NNI) defines
nanotechnology as ‘‘the understanding and control of matter at
dimensions between approximately 1 and 100 nanometers, where
unique phenomena enable novel applications’’ [26,27]. In
addition, there exist nanomedical studies which include materials
at higher scales, e.g. considering structures with at least one
dimension that reaches up to 300 nanometers [7], or 500
nanometers [28], or, at the lower end of the scale, those that are
even smaller than 1 nanometer [29,30].
Criteria that can distinguish between nano and non-nano drugs
and devices are still under discussion, suggesting the urgent need
for ways to define what are nanomaterials and nanotechnology
products from their existing descriptions in the literature and in
CT reports. For instance, in Europe, a broad range of
characteristics—such as the size distribution or the volume-specific
surface area—is used to define a nanomaterial [31,32], even
though size is still the key element for distinguishing products at
the nanoscale. European recommendations consider not only
single or primary particles but also agglomerates—‘‘clusters of
molecules or particles resulting from a process of contact and
adhesion whereby dispersed molecules or particles are held
together by weak physical interactions, which can be dispersed
again’’ [33]—, aggregates—‘‘clusters of chemically-bound nano-
particles held together by strong chemical or sinter forces through
a non-reversible process’’ [33]—, and structured particles, but do
not apply any universal threshold to their size. The most recent
definition [34] considers that a nanomaterial should fulfill at least
one of the following conditions: i) consists of particles, with at least
one external dimension in the size range 1–100 nm for more than
1% of the number size distribution; ii) has internal or surface
structures in at least one dimension in the size range 1–100 nm;
and, iii) has a specific surface area by volume greater than 60 m2/
cm3. In the USA, according to the Food and Drug Administration
(FDA), nanotechnology products must have at least one dimension
in the nanoscale (1–100 nanometers) or, in the case of products
with a size range of up to one micrometer, they must exhibit
properties and phenomena that are attributable to their dimen-
sion(s) and distinct from those of macroscale materials [35].
Consequently, researchers use different measures and properties to
distinguish between nano and non-nano products, ranging from
size, size distribution and surface area, to other material
properties, such as crystalline phase, photocatalytic activity, zeta
potential, or water solubility, among many others.
Online Clinical Trial Registries
Full disclosure of CT outcomes is essential to avoid duplication
of efforts in clinical research, as well as bias in the publication of
results—for instance, selective reporting based on the commercial
interests or failure to report important adverse events [36]. In most
cases, pharmaceutical and commercial data are confidential and,
therefore, additional and more effective sharing policies on clinical
results are still needed.
Registration and public access to CT results have been
frequently discussed [37–41]. In 2004, the International Commit-
tee of Medical Journal Editors (ICMJE) published a statement
establishing the disclosure of clinical trial results in public registries
as a requirement for their publication in scientific journals [42].
Staggered public release of CT results started in 2007 after several
legal rulings [43–45] were made regulating public access to CT
summaries. Nowadays we can find numerous databases offering
free online access to data reported about CTs, such as, for
instance, the ClinicalTrials.gov database (http://clinicaltrials.gov/)
in the USA [46], the EudraCT database accessible through the
European Union Clinical Trials Register (https://www.
clinicaltrialsregister.eu/) [47] and the Japan Medical Association
Clinical Trials Register (JMACTR) (https://dbcentre3.jmacct.med.
or.jp/jmactr/Default_Eng.aspx/). There is still no single compre-
hensive international registry of CTs but the International Clinical
Trials Registry Platform (ICTRP) (http://apps.who.int/
trialsearch/Default.aspx/), developed by the World Health Orga-
nization (WHO), includes these databases, while offering a uniform
access mechanism to clinical trial data stored on them [48]. There
are also several public repositories focused on specific diseases. For
instance, the National Cancer Institute provides an online
searchable database (http://www.cancer.gov/clinicaltrials/
search/) with about 37,000 cancer-related CTs. Additionally, some
databases owned by the pharmaceutical industry can also be
accessed through the Internet, such as the GlaxoSmithKline
Clinical Study Register (http://www.gsk-clinicalstudyregister.
com/; https://clinicalstudydata.gsk.com/) [49]. Even though all
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of these are valuable resources for clinical researchers in the
biomedical and nanomedical areas, none of them makes an explicit
and clear category distinction between CTs supporting nano and
non-nano products.
The work presented in this paper analyzes CT summaries
extracted from the ClinicalTrials.gov database. Since its release in
2010, the ClinicalTrials.gov database has grown considerably
(Figure 1) and several tools have been developed to extend and
improve its functionalities [50,51]. At the time of writing, the
database provides access to about 150,000 registries of CTs
conducted in 185 different countries, including clinical studies on
nanoparticle formulations and medical products containing
nanomaterials and nanodevices. We selected this database among
many others due to its volume of data, its scope and quality, as well
as its programmatic interface, which allows users to download
study record data in a machine-readable format (eXtensible
Markup Language, XML) that can be easily analyzed.
Overall aim of this work
In this paper, we present a novel approach to the classification
of summaries of CTs between those that were targeted at testing
nanotechnology products vs. those targeted at testing conventional
drugs, and demonstrate the feasibility of applying automatic
methods to produce such a classification for the purpose of
annotation and indexing. The obtained results are promising,
suggesting that the CT summaries archived in ClinicalTrials.gov
do contain the required information for a machine learning
method to automatically identify whether the summary refers to a
CT involving nanoparticles and/or nanodevices or not. The
possibility of automatically distinguishing CTs that support nano
vs. those that support non-nano products is timely and necessary
due to the growing information challenges posed by nanomedical
research which make manual comprehensive detection of nano
trials from CT summaries by experts increasingly difficult and
costly, as well as tedious and error-prone.
Materials and Methods
To address the classification problem described above, we
identified, selected and extracted 500 nanodrug-focused CTs from
ClinicalTrials.gov. In addition, we created a control group
composed of 500 CTs not involving any nanodrugs or nanode-
vices. Both sets define our training and test set, and form the
baseline reference set composed of documents correctly labeled as
nano and non-nano (Table S1). We applied state-of-the-art
machine learning methods —reported in the scientific literature
to be suitable for the document classification task, as we will see
next— to generate multiple classification models that were
assessed using cross-validation (both 10-fold and leave-one-out
cross validation).
This section describes the proposed approach in detail. First, we
define the scope of our study as well as the procedure we followed
to identify, select and gather the CT summaries to build the
training and test set. Then, we describe the different methods we
used to conduct the experiments, including the data pre-processing
techniques and the machine learning algorithms that we applied
for document classification. The section concludes with a
description of the validation processes we used to compare the
performance of the generated models for classifying CTs.
Scope of the analysis
We manually selected a representative set of CT summaries
from the ClinicalTrials.gov repository, based on the criteria and
procedures described next. First, we conducted a simple search
browsing studies by keyword: i) those CTs containing the term
‘‘nano’’ (for which 55 results were found) and, ii) those CTs
containing the term ‘‘nanoparticle’’ (which yielded 133 results). It
should be noted that the ClinicalTrials.gov database does not
allow searching by prefix, which prevented us from searching all
the terms that start with the prefix ‘‘nano’’. In order to make this
first search as general as possible and avoid the use of terms related
to a specific drug, we selected the words ‘‘nano’’ and ‘‘nanopar-
ticle’’ as search terms. Such as small total of 188 CT registries
Figure 1. Total number of registered clinical studies in EudraCT and ClinicalTrials.gov over the last years.
doi:10.1371/journal.pone.0110331.g001
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manually validated and labeled as nano, considering the numerous
nanomedical products that are currently present in CTs, suggests
that detecting the use of nanodrugs and nanodevices as being
involved in a CT by using simple keyword searches on their
summary descriptions may not yield all documented examples of
this type of CT.
Therefore, to detect the presence of concepts and semantic
entities that might be related to the nanomedicine field within the
registries of the ClinicalTrials.gov database, we enriched our set of
search terms by including specific concepts from an external
source developed by the National Cancer Institute, the NCI
Metathesaurus [52]. The NCI Metathesaurus combines a large
number of clinically and biologically relevant controlled vocabu-
laries and terminologies (http://ncim.nci.nih.gov/ncimbrowser/
pages/source_help_info.jsf), some directly related to nanotechnol-
ogy and, specifically, to nanomedicine, such as the NanoParticle
Ontology (NPO) [53]. The goal of this step was to select the most
descriptive terms that appear in nanomedical studies from this
broad set of sources. For this purpose, we searched the
terminology database for those entries containing the term ‘‘nano’’
in any field. This search returned more than 800 related
biomedical concepts that were manually filtered afterwards,
selecting only those concepts that belonged to one of the five
semantic types considered potentially relevant to the nanomedical
domain: Organic Chemical; Pharmacologic Substance; Inorganic
Chemical; Biomedical or Dental Material; and, Indicator,
Reagent, or Diagnostic Aid. Other semantic types were disre-
garded due to their lack of relevance for our study—e.g.
Amphibian, Natural Phenomenon or Process, Plant, Eukaryote,
etc. A total of 168 concepts were retrieved and validated, from
which we obtained 433 terms by including all the synonyms
pointed to by the Metathesaurus. We followed a dictionary-based
approach by using the selected concepts provided by the
Metathesaurus as input—i.e. as keywords—for conducting a new
set of searches within the ClinicalTrials.gov database. Only 38
concepts (190 terms) extracted from the Metathesaurus returned
results and were matched to clinical summaries. With this process,
we retrieved a total of 344 CT registries that we validated and
annotated with the label nano after a preliminary manual
verification by us.
Using this combination of searches, we increased the set of
potentially nano CT summaries to 414. This set was then analyzed
in-depth: for each nano candidate, we conducted a comprehensive
study of the intervention involved, checking out external data
about the active component of the drug, its manufacturing process
and the routes of administration. Targeted searches in diverse
Web sources, such as PubMed (http://www.ncbi.nlm.nih.gov/
pubmed/), the Web of Knowledge (http://wokinfo.com/), the
Cochrane Library (http://www.thecochranelibrary.com/), Goo-
gle, and a number of CT online registries, were carried out to
retrieve nanodrug descriptions, which led to a myriad of sources.
The scientific literature, for instance, provided us with a wealth of
descriptions, usually reported as free-text entries. The authors also
consulted a number of additional sources, including drug
databases—e.g. Drugs@FDA (http://www.accessdata.fda.gov/
scripts/cder/drugsatfda/), DailyMed (http://dailymed.nlm.nih.
gov/dailymed/about.cfm/), TOXNET (http://toxnet.nlm.nih.
gov/index.html/), ChemIDplus (http://chem.sis.nlm.nih.gov/
chemidplus/)—, nanomaterials databases—e.g. Nanomaterial
Registry (https://www.nanomaterialregistry.org/) [54]), pharma-
ceutical registries—e.g. Clinical Trials Portal of the International
Federation of Pharmaceutical Manufacturers & Associations
(http://clinicaltrials.ifpma.org/clinicaltrials/no_cache/en/clinical-
trial-advanced-search/index.htm/)—, manufacturer websites—e.g.
COMAR International database for certified reference materials
(http://www.comar.bam.de/en/), European Reference Materials
online catalogue (http://www.erm-crm.org/Pages/ermcrmCata
logue.aspx/), BAM Federal Institute for Materials Research and
Testing list of nanoscaled reference materials (http://www.nano-
refmat.bam.de/en/)—, patent records—e.g. PATENTSCOPE
(http://www.wipo.int/patentscope/en/), Patent Full text Databases
of the US Patent and Trademark Office (http://patft.uspto.gov/)—,
and CT directories developed by advocacy organizations—e.g.
American Association for Cancer Research SU2C Clinical Trials
Finder (http://www.emergingmed.com/networks/AACR-SU2C/),
International Myeloma Foundation trials searcher (http://myeloma.
org/ResearchMatrix.action?tabId=26&menuId=0&queryPageId=1
4). Further, related CTs extracted from ClinicalTrials.gov, EUCTR,
ICTRP and other sources, were also checked for comparison with a
wide set of pre-clinical drugs. Information from all of these sources
were used to cross-check and verify the nature of the drugs,
formulations and medical devices identified as nanodrugs or
nanodevices within the set of CTs earlier retrieved from Clinical-
Trials.gov. From the analyzed information, we found a set of widely-
used terms related to nanomedicine that can be considered as text
patterns in clinical trials—e.g. liposomal, micelle, nanomaterial,
nanosuspension, nanocolloid, crystal, nanotubes, gel, PEG, etc.
These terms were also used to complete our search criteria and
perform new searches in the ClinicalTrials.gov database that allowed
us to retrieve additional clinical trial registries to complete the nano
body of CT summaries. This body of documents was further double-
checked by experts in the field of nanotechnology— Prof. Alejandro
Pazos and Prof. Julia´n Dorado (University of A Corun˜a, Spain), as
external experts, and Prof. Vı´ctor Maojo and Prof. Casimir
Kulikowski (co-authors)—, eliminating CTs that did not belong to
nanomedicine and disregarding incomplete and inaccurate entries in
the registries. Finally, the CTs involving non-nano products were
randomly selected—i.e. without performing any specific query in
ClinicalTrials.gov—and subsequently reviewed yet again to remove
those CTs involving any relation to nanodrugs or nanodevices—with
the few thus removed then becoming candidates that were
considered to augment the set of CT nano entries. As result, we
ended up with balanced training and testing sets, including 500 nano
CTs and 500 non-nano CTs. For computational purposes, we
downloaded the selected registries from the ClinicalTrials.gov
website and stored all the study record data locally. Each record,
in XML format, was processed with the Python library lxml (http://
lxml.de/) to extract its textual content.
Through the procedure described above, we obtained the set of
1000 classified summaries, divided into the two different classes of
nano and non-nano, depending on whether they were relevant or
not to the targeting of nanoparticles or nanomaterials, or
nanotechnologies, and hence falling into the nanomedical domain.
This set of summaries (Table S1) provided the basis for the
development and training of several types of classifiers, as
described in the following subsections.
Data Pre-processing
Data pre-processing is a critical step for improving classifier
performance, which strongly depends on the data used to train the
models [55]. To apply machine learning techniques and facilitate
knowledge discovery during training, we first pre-processed all the
documents (CT summary records) to eliminate irrelevant infor-
mation from them. We performed several data standardization
and filtering steps before running the data analysis, as detailed
below.
For each entry (CT record), the textual content was tokenized
and pre-processed using the Natural Language Toolkit (nltk)
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package for Python (http://nltk.googlecode.com/svn/trunk/doc/
api/nltk-module.html) [56]. First, we split plain text into tokens by
resorting to regular expressions: blank characters and punctuation
marks provided the initial division into tokens. Tokens are defined
as sequences of alphanumerical characters that may also include
the underscore character (‘_’). Next, we replaced all the digits in
the text by an arbitrary character (‘#’) and converted all text to
lowercase. Stop words and short textual features were removed
from the text, disregarding those tokens with less than three
characters, as recommended in [57]. Then, we performed word
stemming using Porter’s algorithm for English [58], grouping
words belonging to the same family by reducing them to their
common stem.
Next we converted the plain text into textual features—
unigrams and bigrams. A unigram can be defined as a single
token extracted from the text while bigrams can be regarded as
pairs of consecutive tokens found in the text. Each CT was
represented as a vector of features implementing a ‘‘bag-of-words’’
approach [59], each component of the vector being either a
unigram or a bigram. Table 1 shows a summary of the number of
features—unigrams and bigrams—identified in the documents to
illustrate their average size. For all documents in the collection, a
total number of 11,164 unigrams and 38,124 bigrams were found.
Each unigram occurred, on average, in 24 documents, while each
bigram appeared in 6.3 documents. Related graphical summaries
of results are provided in the Supporting Information, in Figures
S1 and S2. These figures show that the distribution of N-grams per
document —both unigrams and bigrams— is not normal, with a
median of the distribution being 522,875 (unigrams per document)
in the case of unigrams, and 297,667 (bigrams per document) in
the case of bigrams.
As stated above, we adopted a vector-based representation for
the documents. Therefore, each document can be regarded as a
vector with each of its components corresponding to a unique
feature —unigram or bigram— in the collection. We built the
features vector for our collection of 1000 documents using
different representations:
1. Binary representation: each component of the vector denotes
whether a unigram or bigram is present (1) or not (0) in the CT
represented by the vector.
2. Frequency-based representation: in this representation we
record the frequency of appearance of each feature (i.e.
unigram or bigram) in the document.
3. Inverse Document Frequency-based (IDF) representation, which
eliminates those terms that appear in too many documents,
being therefore unlikely to discriminate well between the
classes.
4. Term Frequency*Inverse Document Frequency-based (TFIDF)
representation: Using this transformation it is possible to
combine the local discrimination power of a term—i.e. in the
context of a single document— with the global discrimination
power of the term—in the context of the whole collection [60].
Finally, we also chose to normalize the resulting feature vectors.
We applied a normalization step to all the representations above:
each document vector was scaled by its l2 –norm. The purpose of
this normalization was to optimize the performance of certain
classifiers, especially those implemented with the simple Naı¨ve
Bayes [61] and Support Vector Machine algorithms [62,63].
Design of the experiment
We trained several classifiers to find the best machine learning
model for predictively categorizing the corpus documents into the
nano and non-nano classes. We built the following classifiers using
the collection of state-of-the-art machine learning algorithms for
data mining provided by the Weka workbench (http://www.cs.
waikato.ac.nz/ml/weka/) [64]:
1. Multinomial Naı¨ve Bayes (MNB) classifier: This variation of
the Naı¨ve Bayes classifier, based on a multinomial distribution,
is typically used for document classification [65]. Although it
makes strong assumptions—e.g. mutually independent vari-
ables—it can yield good results in terms of precision and is
often used as the simplistic baseline for comparison with other
classifier results.
2. Decision trees (C4.5): We built a C4.5 decision tree [66] using
the open-source implementation provided by Weka, named
J48 [67].
3. Logistic regression classifiers: Logistic regression [68] is a
method for linear classification that models how the probability
of an event can be affected by one or more parameters. We
used three different variants of logistic regression:
Table 1. Statistics related to the number of features found in the body of CT summary documents.
Unigrams Bigrams
Number of unigrams
Number of unique(*)
unigrams Number of bigrams
Number of unique(*)
bigrams
Minimum number of N-grams per
document
111 66 45 31
Maximum number of N-grams per
document
15092 1277 13124 1449
Average number of N-grams per
document
732.462 268.282 450.179 240.772
Standard deviation 1000.856 138.014 788.709 167.367
The ‘‘Minimum number of N-grams per document’’ and the ‘‘Maximum number of N-grams per document’’ refer to the number of N-grams (both allowing and not
allowing double- count) found in the documents containing the smallest and greatest number of N-grams in the collection, respectively. For instance, regarding
unigrams, the document containing the smallest number of unigrams allowing double-count contains 111 unigrams, while the document containing the smallest
number of unigrams not allowing double-count contains 66 unigrams.
(*)no double-count allowed
doi:10.1371/journal.pone.0110331.t001
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a. Stochastic Gradient Descent (SGD) algorithm for binary class
logistic regression [69].
b. Regularized logistic regression, where we applied regulariza-
tion to the regression parameters to reduce overfitting—a
condition which occurs when a classification or estimation
model is too complex (too many parameters with respect to
the number of observations) since it is trying to over-precisely
fit training data instead of learning to generalize.
i. L1-regularized Logistic Regression (L1-LogReg) or lasso
regression [70], where we used the L1-norm as regularization
parameter.
ii. L2-regularized Logistic Regression (L2-LogReg) or ridge
regression [71], where the penalty parameter was the L2-
norm.
4. Support Vector Machines (SVM): SVM algorithms [72] have
been widely used to model large feature spaces and,
particularly, have proven successful when applied to document
classification problems [62]. To find the optimal method for
our dataset, we compared the performance of several SVM
kernel types, obtaining the best performance for the following
kernels:
a. SVM-Lin: A SVM with a linear kernel.
b. SVM-Pol: A SVM with a polynomial kernel of degree 2, using
the Sequential Minimal Optimization (SMO) implementation
[73,74].
Independent experiments were run for each classifier. We
evaluated their generalization performance on the selected
datasets corresponding to the various document representations
previously explained: occurrence matrices, frequency matrices,
IDF, TFIDF, and their normalized versions.
The entire dataset of 1000 CTs was divided into training and
testing sets for which classifiers were tested by 10-fold Cross-
Validation (10-fold CV) and Leave-One-Out (LOO) methods. In
the case of 10-fold CV, the entire CT summary data set was
randomly stratified into ten folds of the same size and each fold
was composed of 100 CTs with the same number of nano and
non-nano CTs. For the leave-one-out or LOO tests, we used one
CT record from the original body of data as a test example, while
the remaining records (999) were used as the training set to
develop the model. This was iterated 1000 times by leaving out
each of the data items. This type of validation yields a more
conservative approach to test the classifier performance [75,76].
Finally, we also carried out self-consistency tests where the
complete body of documents was included in the training set to
see if the generated models differed much from the cross-validated
ones. These tests give a measure of the stability of the classifier
design as a function of the statistical variance across the different
training subsets in the cross-validations, in comparison to the over-
optimistic performance expected from the over-fitted testing-on-
the-training set classifier based on the entire body of 1000
documents.
The validation of the different models was conducted consid-
ering several performance measures:
- True Positive vs. False Positive rates.
- Precision, for measuring the positive predictive value.
- Recall, which measures the sensitivity.
- F-Measure, which combines precision and recall into a single
measure.
- Mathews Correlation Coefficient [77], which measures the
correlation between the observed and the predicted class for
binary classifiers.
- The AUC, or Area Under the Curve, of the ROC [78,79],
which provides a combined measure of sensitivity and
specificity, useful for overall classifier comparison as it
integrates results over all possible tradeoffs of decision
threshold along the ROC curve.
These outcome measures allowed us to evaluate, compare and
rank the diverse models generated during our experiments in
order to select the best method to address the problem of
classifying CTs and validate our approach. Figure 2 presents an
overview of the different steps of the method described in this
section.
Results and Evaluation
In this section, we provide a summary of the best results
obtained during the above described experiments. Complete
results from experiments on unigrams and bigrams are provided in
the Supporting Information section (Figures S3 to S5). The reader
can find there several comparisons of the results provided for the
different document input sets and classifiers.
Performance
Table 2 presents a comparison of the results provided by the
best two learning algorithms under the different transformations
using 10-fold CV and LOO, for unigrams. The results yielded by
bigram-based models are provided in the Supporting Information
Section, since they were outperformed by unigram-based models.
As shown in the table, in the case of unigrams, the best
performance results were obtained using L1-normalized logistic
regression with the IDF transformation. This regression model
produced the best classifier with 10-fold CV as well as with LOO
experiments. Figure 3 shows the learning curve for this best
empirical classification model for both types of validation. The
learning curve represents the prediction accuracy (percentage of
correct results) vs. the training set size (number of training
examples) and it is useful to see whether the machine learning
classifier is suffering from bias or overfitting. The learning curve
shows changes in the learning rate as more documents were added
to our corpus. For its calculation, we ran several experiments
increasing the size of the training set incrementally —creating a
10% training set and 90% test set from the original dataset, then
successively reducing the test set until it comprised only 5% of the
overall dataset—, and plotted the accuracy as a function of the
cardinality of the training set. For the gradual incrementation of
the training set size, in the Advanced Mode of the Weka
Experimenter, we used the CrossValidationResultProducer (for
varying the number of instances a classifier is trained on) in
conjunction with the LearningRateResultProducer (to generate
the learning curve results). The learning curve in Figure 3 tends to
increase as we add more training examples. This does indeed
suggest that the selected algorithm is learning with experience,
showing that it is adequately reflecting the pattern of the data set
without undue over- or under-fitting.
On the other hand, Figure 4 shows the ROC curve for a subset
of the tested classifiers, including those classification models with
the best values for the Area Under the Curve (AUC) measure. The
AUC, as an overall threshold-independent statistic to compare
classifier performance, indicates the ability of the classifier to
distinguish between the nano and non-nano classes. In addition,
Cohen’s Kappa statistics [80] for these binary models are given in
Machine Learning to Identify Nanodrugs in CTs from ClinicalTrials.gov
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Figure 2. Illustration of the followed approach.
doi:10.1371/journal.pone.0110331.g002
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Table 3. This coefficient measures the reliability of the results
reflecting the number of correct results obtained by the classifier
not by chance. In the case of the L1-LogReg classifier with IDF
transformation, we obtained a value of 0.91 for the kappa statistic,
which is close to 1, thus suggesting a high confidence in the
reliability of the classifier.
A comprehensive comparison between the different classifica-
tion algorithms shows that while SVM-based methods offer good
precision results, CT classification is outperformed in most cases
by an approach based on logistic regression classifiers, specifically
by those using the L1-norm penalty. At the same time, logistic
regression has the substantial advantage of producing sparse
models, which can be efficiently implemented.
In the case of regularized logistic regression, L1-regularized
logistic regression yields consistently higher performance than L2-
regularized logistic regression. As reported elsewhere [81], while
numerical stability is provided by L2-regularization, L1-regular-
ization yields sparse models and tends to provide better
performance for input datasets that include non-discriminating
features. In fact, by applying L1-regularized logistic regression we
carry out a feature selection process, which considerably improves
the results. Finally, when catalyzed by a stochastic gradient descent
algorithm, logistic regression eventually outperforms other state-
of-the-art algorithms, such as SVM.
For SVM-based models, the linear kernel implementation
yielded the best results in most cases. However, we found the
SVM polynomial classifier to perform better with normalized
datasets. This can be explained due to the fact that SMO
implementation we used for the polynomial kernel SVM notably
augments its performance with small numeric attributes [73] —i.e.
when data is normalized. Conversely, the SVM polynomial kernel
offers low performance results when applying the IDF transfor-
mation and, more concretely, the TFIDF transformation to non-
normalized datasets. This indicates that, in this case, we may be
using a too complex algorithm for training our model: the
polynomial kernel model contains more information about the
training data, but it causes overfitting and does not generalize well
to new data. This problem is avoided by normalizing the input
data sets, using the normalized versions of IDF and TFIDF, as
shown in Figures S3 to S5 in the Supporting Information. Hence,
we have smaller values for the features, which correspond to a
simpler (smoother) hypothesis that may be easier to generalize to
unseen data. Although this regularization prevents overfitting, we
can conclude that a simpler model, such as the linear kernel, is
more suitable in this case, due to its lower computational cost.
As mentioned previously, we also tested several SVM kernels
that are, in general, more flexible than linear and polynomial
kernels. For instance, we tested the Radial Basis Function (RBF)
kernel, which tends to yield smoother solutions than linear and
polynomial kernels, making it more suitable for other type of data
rather than text, such as those arising in the classification of
images. In fact, the good performance of polynomial kernels relies
on the hypothesis that high-order word correlations provide more
information than single words. We could not conclude whether
this correlation between words prevails or not in our body of
documents, but, based on the results, we found that single tokens
perform better than bigrams. The use of unigrams outperforms the
results obtained with bigrams, which could be due to a lack of
correlation between adjacent words. This is consistent with the
nature of the textual contents of the CTs classified as nano. It
should be stressed that, while nano CTs contain terms from the
nanotechnology field, in most cases, they are acting as simple
‘‘modifiers’’ to biological or medical referents. Therefore,
nanomedical terms usually occur as single (though composite)
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words rather than as bigrams, and tend to be sparse in the text.
However, these performance results might also suggest that
bigrams require a larger set of documents to obtain significant
results than unigrams, since the number of indexing terms for
bigrams may be significantly larger —thus introducing noise—,
and bigrams are less likely to occur in a document than unigrams
—considerably lowering performance for small datasets.
With regards to the other classifiers evaluated in the experi-
ments, as reported elsewhere [65], the multinomial Bayesian
(MNB) performance is worse than the state-of-the-art, and thus we
just used it as a baseline method for comparison purposes.
However, as shown in Figures S3–S5, MNB performs better when
using TFIDF scores instead of raw term frequencies [61],
especially when no normalization is applied to the length of the
resulting feature vectors.
On the other hand, C4.5 decision trees are not usually applied
to datasets with a large number of features for efficiency reasons,
but they are useful for interpreting the decisions of a classifier
involving a conjunction of features. Moreover, in some cases, they
yield a good performance—e.g. when the input set has a high
Figure 3. Learning curve for L1-regularized logistic regression in the case of unigrams with IDF transformation.
doi:10.1371/journal.pone.0110331.g003
Figure 4. ROC curve for the best classification models resulting from the LOO validation (ranking based on the AUC obtained for
each classifier).
doi:10.1371/journal.pone.0110331.g004
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number of highly discriminating subsets of subspaces of features.
As can be seen in the Supporting Information section, for
unigram-based experiments, C4.5 outperforms other classifiers—
such as logistic regression or polynomial SVM— for different
transformations of the documents vector. Conversely, for bigrams,
it yields the worst performance results for the most of the
experiments. This is consistent with the earlier comment on the
nature of the ‘‘nano’’ term being a common modifier of
biomedical referents in the text, making the resulting composite
words sufficiently powerful discriminating unigrams for the
analysis, so that adjacent words simply add confusing "noise" to
the signal that then must be detected during the classifier’s
learning phase.
It is also significant that feature transformation dramatically
improves the performance of the different methods in several
experiments. Regarding the different representations of the input
dataset, IDF provides the best results, suggesting that while the
local weight of a term is a good discriminant, its global weight
usually provides a better discriminating performance. With respect
to normalization, the SVM linear classifier yields better results for
normalized data, while L1- and L2-normalized logistic regression
offers better performance without normalization. While normal-
ization tends to improve performance results for most experiments,
this is not the case for regularized logistic regression, where
normalization appears to inject noise into the dataset.
Computational cost
In terms of the computational cost of the different classification
models, we can make a few observations. Despite the fact that
SVM algorithms achieved the state-of-the-art performance, they
have a high computational cost, especially when using SVM non-
linear kernel classifiers, which are much more complex compu-
tationally than linear kernels. In our study, the SVM linear
classifier shows close-enough performance to the polynomial
kernel classifier regardless of the transformations applied to the
input dataset with a much lower computational cost.
However, logistic regression yields better results in terms of
computational efficiency. Compared to SVMs, the drawback of
logistic regression is that it usually requires an expensive
exponential function evaluation during the numerical optimiza-
tion. But, as suggested elsewhere [82,83], L1-regularized logistic
regression can outperform more recent algorithms for a wide
range of classification tasks—as it did for our classification
problem—and, in addition, it produces sparse models—with
many zero regression parameters— thus reducing the computa-
tional complexity. On the contrary, L2-norm provides dense
solutions, increasing the computational cost of the classification.
In summary, in this series of experiments, L1-regularized
logistic regression and SVMs produce similar results and
significantly outperform the rest of the tested classifiers. We can
conclude that, as far as computational cost and performance trade-
off are concerned, the L1-norm logistic regression emerges as the
best choice for our CT summary document classification problem.
Discussion
This paper makes an original contribution to the design,
modeling and analysis of the nanomedicine domain in terms of
showing that one can automatically detect the relevance to a nano-
related target from a CT summary in ClinicalTrials.gov. We have
created an annotated body of nanomedicine CTs, with training
and testing sets that can be used to develop extended computa-
tional applications for supporting research in the nanomedicine
field (see Table S1 within the Supporting Information). To the best
of our knowledge, there is no such publicly available reference
dataset for clinical nanomedicine. Our approach has produced
promising results: given a subset of CTs extracted from
ClinicalTrials.gov, our method can be reliably used for automat-
ically determining whether the CT involves the use of nanodrugs.
We identified an algorithm (L1-regularized logistic regression) able
to deal with such a high-dimensional problem, both in terms of
classification performance and computational cost. Although the
classification results we obtained in this study are not directly
comparable to those resulting by other similar state-of-the-art
studies—since the latter are focused on different domains and
resort to different training and test sets, in general, our results (F =
0.955) outperform the results from other recent experiments—that
range in the interval [0.85, 0.96] by F-measure—as reported
elsewhere [65,84–89]. To our knowledge, these results are the first
application of text mining to extract information about nanodrugs
and nanodevices from ClinicalTrials.gov, excluding the NanoSif-
ter [90], which covers the dendrimer domain alone.
There are a number of reasons that justify performing such a
categorization of CTs into the nano vs. non-nano categories. These
include, for instance, comparing legacy formulations with nano-
technology-based formulations —in terms of aspects such as
structure, function, toxicology, pharmacokinetics and pharmaco-
dynamics (PK/PD), clinical immunogenicity, safety and effective-
ness—, which would provide additional information to researchers
in the nano domain. This knowledge could lead to the reuse of
existing products that could be manufactured at the nanoscale
and, therefore, re-classified as nanotechnology once this is done. In
most cases, current CTs on nanodrugs have not revealed unknown
side effects due to the nanoparticle or any of its constituents. Yet,
earlier abandoned therapeutics agents that have now been
reformulated as nanodrugs are presenting toxicity and side effects
due to the special physicochemical properties acquired during the
nanomanufacturing process that were not considered during the
design of the original drug [6,91]. While safety and efficacy trials
Table 3. Kappa statistic for the best classification models resulting from the Leave-One-Out validation.
Classifier Kappa coefficient
L1-Logistic Regression IDF 0.91
L1-Logistic Regression Frequencies 0.864
L1-Logistic Regression Binary Occurrences 0.832
SVM Linear Normalized TFIDF 0.826
L1-Logistic Regression TFIDF 0.824
SVM Linear IDF 0.816
doi:10.1371/journal.pone.0110331.t003
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will, of course, still remain essential, our approach could
considerably simplify and reduce the steps involved with the need
to pursue, as currently, assays and clinical trials, by instead
extrapolating clinical data and using modeling and simulation
tools from the related prior experiments.
In addition, physicians —and concerned patients— are currently
increasingly interested in CTs on non-nano drugs, since they often
seek information about diagnosis and/or therapy for a given disease.
On the other hand, most nano CTs currently archived in
ClinicalTrials.gov are in an early stage —either phase I or phase
II—, being those more targeted at clinicians and researchers —and
even pharmaceutical and nanotechnology companies— who are
more interested in research or the mid-term or long-term
applications of nanodrugs. In addition, different users will likely
search for different information. For instance, nano users often
search for information about the composition and characterization
(e.g. size, cytotoxicity, ligands, hydrosolubility, bioavailability,
pharmacokinetics etc.) of the nanocompound, while physicians are
more interested in the patient profile (e.g. sex, race, age, etc.), drug
dosage, study arms, etc. Knowing in advance the category to which a
given CT belongs, would ease the way information is indexed,
searched and presented to users based on their likely interests and
goals, which could be deduced or inferred from their profiles.
The information about nano CTs available in ClinicalTrials.gov
—although the same applies to other existing registries such as those
cited in the introduction— is not currently connected to other
repositories involving related data, such as physicochemical
properties (caNanoLab, https://cananolab.nci.nih.gov/caNano
Lab/), biological interactions (Nanomaterial-Biological Interactions
Knowledgebase, http://nbi.oregonstate.edu/), normalized vocab-
ularies and ontologies (the Unified Medical Language System,
http://www.nlm.nih.gov/research/umls/, and the NanoParticle
Ontology, http://www.nano-ontology.org/), environmental and
health safety data (the Nanomaterial Registry, https://www.
nanomaterialregistry.org/), modeling and simulation experiments
(nanoHub, http://nanohub.org/), etc. We believe that once the
nano CTs have been automatically identified, it is possible to
establish links among related information —either manually or
automatically, using artificial intelligence techniques—, in the same
manner as with most NCBI repositories (http://www.ncbi.nlm.nih.
gov/). Furthermore, the integrated information could be exploited
to compare and curate experimental results that are currently
distributed in different databases. We believe that this rationale
supports the initiative of automatically labeling the existing CTs in
the ClinicalTrials.gov database so as to support, assist, and
encourage future research in nanomedicine.
Regarding the limitations of the approach presented here, we
have consulted different CT registries as well as drug registries,
Pharma websites and other information sources and, unfortunate-
ly, we have run into several barriers, especially related to the
unavailability of public clinical nanomaterial data. We have also
identified several issues concerning the format and nature of the
data reported in CTs. First, the current identification system of
CTs has not been agreed to by consensus, and the main registries
are not fully committed to use a common coding system. Second,
drug nomenclature does not follow a standard, and a large number
of synonyms can be found to designate the same compound,
especially in the nanomedicine area. Finally, CT summaries do
not report the same type of information and do not have a
common structure in terms of text analysis. All of these issues add
complexity to the task of automatically parsing clinical summaries
and result reports —and it is worth noting that a similar situation
arises when analyzing the scientific literature. This fact could
constrain the application of the statistical approach presented in
this paper, since it relies on common patterns and terms that were
found in the documents.
Nevertheless, we believe that our work can stimulate a wide
range of novel computational applications to support nanomedical
research. An interesting example of application is the automated
creation of a repository linking nanoparticles and/or nanodevices
to side-effects reported in the CTs, an idea that we have already
explored [92]. Once an automated CT tagger—i.e. a classification
model that tags CTs as nano or non-nano, like the one presented
in this paper—is available, it is possible to reliably apply text
mining techniques to extract relevant information. This includes
but is not limited to— nanoparticles and nanodevices names and
formulations, their potential side-effects, routes of exposure, etc.
We are currently conducting an analysis of the distribution of the
nanomedical concepts patterns found in the dataset and their
relationships, as well as working on the development of a CT
information retrieval system based on the results obtained from
this work. In addition to CT summaries, this approach could be
applied to the vast nanomedical literature and also adapted to
extract data from other textual sources.
Conclusions
With the volume of experimental and clinical data related to
nanomedicine increasing rapidly, manual analysis and annotation
of studies on nanodrugs has become slow and largely impractical. In
this context, the development of automatic approaches targeted at
discriminating information from the nano and non-nano domains
becomes necessary. In this paper, we have presented two original
contributions to the nanoinformatics field. First, we have created a
training and testing set for a binary textual classification problem
targeted at identifying previously unseen CTs as being nano or non-
nano. Second, we have conducted a thorough review of the state of
the art both on machine learning-based techniques for binary
document categorization and existing repositories of drugs and
registries of CTs. We selected the classification methods and
algorithms reported in the literature as the best performers for
binary text categorization problems and applied these methods to
the training and test sets we created. We selected the most efficient
method to classify CTs into the nano and non-nano categories, thus
producing categorization models whose results outperform most
state-of-the-art classifiers. We believe that such a classifier can help
catalyze the research in translational nanomedicine, thus enabling a
wide range of applications that cannot be addressed well with a raw
repository of unclassified CTs.
The analysis of clinical trials related to nanomedicine, carried
out by integrating reported results over all the different available
databases worldwide, could result in the extraction of potential
correlations, and new patterns and trends in nanomedical data.
The analysis of correlations between multiple pre-clinical and
clinical studies may be of value in areas such as nanotoxicity and
targeted drug therapy, where certain underlying patterns and
trends could support inferences that inform future research in
nanomedicine. By way of an example, results could serve to
compare new formulations with existing ones and determine
additional side effects that may arise due to the newly added
components and/or the manufacturing process (i.e. to the
application of nanotechnology to the original drug). This work
could also facilitate researchers in automatically discovering new
Machine Learning to Identify Nanodrugs in CTs from ClinicalTrials.gov
PLOS ONE | www.plosone.org 12 October 2014 | Volume 9 | Issue 10 | e110331
knowledge from CTs such as, for instance, uncovering potential
toxicity of novel nanodrugs or recruiting patients who are most
likely to respond positively to a certain nanoparticle intervention
due to their participation in earlier CTs using similar drugs.
Shorter time-to-market cycles for nanodrugs and medical
nanodevices require researchers to act on insights faster than
ever, as well as for computer scientists to develop new methods
and tools to efficiently manage this new knowledge, providing
users with the necessary processing and analysis capacity.
Furthermore, publishers, governmental agencies and the Pharma
industry will surely need to develop new open data strategies and
the setting of standards for CT data. This study points out that
valuable data on nanomedical CTs are already available implicitly
within the ClincalTrials.gov repository, and that machine learning
methods can be used to combine the values of individual word-
features from the CT summaries into a predictor for detecting
nano-related CTs. These kinds of approaches are needed to help
gather, organize and integrate the huge volume of existing data
which is potentially relevant for nanomedicine—including pre-
clinical and clinical data—and make them accessible to research-
ers [93].
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